First-in-Human Phase 1 Study of a B Cell– and Monocyte-Based Immunotherapeutic Vaccine against HER2-Positive Advanced Gastric Cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose BVAC-B is an autologous B cell– and monocyte-based immunotherapeutic vaccine that contains cells transfected with a recombinant human epidermal growth factor receptor 2 (<i>HER2</i>) gene and loaded with the natural killer T cell ligand alpha-galactosylceramide. Here, we report the first BVAC-B study in patients with HER2-positive advanced gastric cancer.Materials and Methods Patients with advanced gastric cancer refractory to standard treatment with HER2+ immunohistochemistry ≥ 1 were eligible for treatment. Patients were administered low (2.5×10<sup>7</sup> cells/dose), medium (5.0×10<sup>7</sup> cells/dose), or high dose (1.0×10<sup>8</sup> cells/dose) of BVAC-B intravenously four times every 4 weeks. Primary endpoints included safety and maximum tolerated BVAC-B dose. Secondary endpoints included preliminary clinical efficacy and BVAC-B-induced immune responses.Results Eight patients were treated with BVAC-B at low (n=1), medium (n=1), and high doses (n=6). No dose-limiting toxicity was observed, while treatment-related adverse events (TRAEs) were observed in patients treated with medium and high doses. The most common TRAEs were grade 1 (n=2) and grade 2 (n=2) fever. Out of the six patients treated with high-dose BVAC-B, three had stable disease with no response. Interferon gamma, tumor necrosis factor-α, and interleukin-6 increased after BVAC-B treatment in all patients with medium and high dose, and HER2-specific antibody was detected in some patients.Conclusion BVAC-B monotherapy had a safe toxicity profile with limited clinical activity; however, it activated immune cells in heavily pretreated patients with HER2-positive gastric cancer. Earlier treatment with BVAC-B and combination therapy is warranted for evaluation of clinical efficacy.
Abstract
Purpose BVAC-B is an autologous B cell– and monocyte-based immunotherapeutic vaccine that contains cells transfected with a recombinant human epidermal growth factor receptor 2 (HER2) gene and loaded with the natural killer T cell ligand alpha-galactosylceramide. Here, we report the first BVAC-B study in patients with HER2-positive advanced gastric cancer. Materials and Methods Patients with advanced gastric cancer refractory to standard treatment with HER2+ immunohistochemistry ≥ 1 were eligible for treatment. Patients were administered low (2.5×107 cells/dose), medium (5.0×107 cells/dose), or high dose (1.0×108 cells/dose) of BVAC-B intravenously four times every 4 weeks. Primary endpoints included safety and maximum tolerated BVAC-B dose. Secondary endpoints included preliminary clinical efficacy and BVAC-B-induced immune responses. Results Eight patients were treated with BVAC-B at low (n=1), medium (n=1), and high doses (n=6). No dose-limiting toxicity was observed, while treatment-related adverse events (TRAEs) were observed in patients treated with medium and high doses. The most common TRAEs were grade 1 (n=2) and grade 2 (n=2) fever. Out of the six patients treated with high-dose BVAC-B, three had stable disease with no response. Interferon gamma, tumor necrosis factor-α, and interleukin-6 increased after BVAC-B treatment in all patients with medium and high dose, and HER2-specific antibody was detected in some patients. Conclusion BVAC-B monotherapy had a safe toxicity profile with limited clinical activity; however, it activated immune cells in heavily pretreated patients with HER2-positive gastric cancer. Earlier treatment with BVAC-B and combination therapy is warranted for evaluation of clinical efficacy.
참고문헌 (30)
- Bray F, "Global cancer statistics 2018 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185countries", CA Cancer J Clin, 68, pp.394~424 (2018)
- Gravalos C, "HER2 in gastric cancer : a new prog nostic factor and a novel therapeutic target", Ann Oncol, 19, pp.1523~1529 (2008)
- Bang YJ, "Trastuzumab in combination with chemo therapy versus chemotherapy alone for treatment of HER2positive advanced gastric or gastro-oesophageal junction cancer(ToGA) : a phase 3, open-label, randomised controlled trial", Lancet, 376, pp.687~697 (2010)
- Li W, "HER2-tar geted advanced metastatic gastric", gastroesophageal junction adenocarcinoma : treatment landscape and future perspec tives, 2022, pp.10, 71~
- Shitara K, "Trastuzumab deruxtecan in previously treated HER2positive gastric cancer", N Engl J Med, 382, pp.2419~2430 (2020)
- Mitani S, "Emerging targeted therapies for HER2 positive gastric cancer that can overcome trastuzumab resistance", Cancers(Basel), 12, pp.400~ (2020)
- Fuchs CS, "Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gas troesophageal junction cancer : phase 2 clinical KEYNOTE-059trial", JAMA Oncol, 4, pp.e180013~ (2018)
- Kang YK, "Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens(ONO-4538-12, ATTRACTION-2) : a randomised, double-blind, placebo-con trolled, phase 3 trial", Lancet, 390, pp.2461~2471 (2017)
- Moehler M, "LBA6_PR nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer", gastroesophageal junction cancer (GC, esophageal adenocarcinoma (EAC): first results of the Check Mate 649 study, pp.Ann Oncol, 2020[DOI]
- Janjigian YY, "First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer : an open-label, single-arm, phase 2 trial", Lan cet Oncol, 21, pp.821~831 (2020)
- Janjigian YY, "The KEYNOTE-811 trial of dual PD-1 and HER2 block ade in HER2-positive gastric cancer", Nature, 600, pp.727~730 (2021)
- Yang L, "Use of immunotherapy in the treat ment of gastric cancer", Oncol Lett, 18, pp.5681~5690 (2019)
- Neelapu SS, "Axicabtagene ciloleucel CAR T-cell ther apy in refractory large B-cell lymphoma", N Engl J Med, 377, pp.2531~2544 (2017)
- Ma S, "Current progress in CAR-T cell therapy for solid tumors", Int J Biol Sci, 15, pp.2548~2560 (2019)
- Ko HJ, "Immuno suppressive myeloid-derived suppressor cells can be convert ed into immunogenic APCs with the help of activated NKT cells : an alternative cell-based antitumor vaccine", J Immunol, 182, pp.1818~1828 (2009)
- Choi CH, "Phase I study of a B cell-based and monocyte-based immu notherapeutic vaccine, BVAC-C in human papillomavirus type 16-or 18-positive recurrent cervical cancer", J Clin Med, 9, pp.147~ (2020)
- Kim EK, "Enhanced antitumor immunotherapeutic effect of B-cell based vaccine transduced with modified adenoviral vector containing type 35 fiber structures", Gene Ther, 21, pp.106~114 (2014)
- Lee JB, "First in-human phase I study of BVAC-B cell therapy in HER2positive advanced gastric cancer", J Clin Oncol, 38(15Suppl), pp.4534~ (2020)
- Simon R, "Accelerated titration designs for phase I clinical tri als in oncology", J Natl Cancer Inst, 89, pp.1138~1147 (1997)
- National Cancer Institute, "Common Terminology Criteria for Adverse Events (CTCAE) v4.03", National Can cer Institute, ~ (2010)
- Martinez M, "CAR T cells for solid tumors : new strategies for finding, infiltrating, and surviving in the tumor microenvironment", Front Immunol, 10, pp.128~ (2019)
- Chavez JC, "CAR T-cell therapy for B-cell lymphomas : clinical trial results of avail able products", Ther Adv Hematol, 10, pp.2040620719841581~ (2019)
- Newick K, "CAR T cell thera py for solid tumors", Annu Rev Med, 68, pp.139~152 (2017)
- Rahma OE, "Therapeutic vaccines for gastrointesti nal cancers", Gastroenterol Hepatol(N Y), 7, pp.517~564 (2011)
- Sundar R, "A phase I", Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer, 2018, pp.18, 332~
- Rosenberg SA, "Cancer immunotherapy : moving beyond current vaccines", Nat Med, 10, pp.909~915 (2004)
- Nicolas-Morales ML, "Peptide-based vaccines in clinical phases and new poten tial therapeutic targets as a new approach for breast cancer : a review", Vaccines(Basel), 10, pp.1249~ (2022)
- Mittendorf EA, "Efficacy and safety analysis of Nelipep imut-S vaccine to prevent breast cancer recurrence : a rand omized, multicenter, phase III clinical trial", Clin Cancer Res, 25, pp.4248~4254 (2019)
- Seo S, "Loss of HER2 positivity after anti-HER2 chemotherapy in HER2positive gastric cancer patients : results of the GASTric can cer HER2 reassessment study 3(GASTHER3)", Gastric Cancer, 22, pp.527~535 (2019)
- Tanaka H, "Mapping the HLA-A24-restricted T-cell epitope peptide from a tumour-associated antigen HER2", neu : pos sible immunotherapy for colorectal carcinomas, 2001, pp.84, 94~99